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Purpose: To determine the role of imaging measurements of emphy-
sema and airway disease in determining chronic obstructive 
pulmonary disease (COPD) symptoms and exercise limita-
tion in patients with COPD, particularly in patients with 
mild-to-moderate disease.
Materials and 
Methods:
Participants (n = 116) with Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) grade U (unclassified) or grade 
I–IV COPD provided informed consent to an ethics board–ap-
proved HIPAA-compliant protocol and underwent spirometry 
and plethysmography, completed the St George’s Respiratory 
Questionnaire (SGRQ), completed a 6-minute walk test for the 
6-minute walk distance (6MWD), and underwent hyperpolar-
ized helium 3 (3He) magnetic resonance (MR) imaging and 
computed tomography (CT). Emphysema was estimated by us-
ing the MR imaging apparent diffusion coefficient (ADC) and 
the relative area of the CT attenuation histogram with attenua-
tion of 2950 HU or less (RA950). Airway disease was measured 
by using the CT airway wall thickness of airways with an in-
ternal perimeter of 10 mm and total airway count. Ventilation 
defect percentage at 3He MR imaging was used to measure 
ventilation. Multivariable regression models for the 6MWD 
and SGRQ symptom subscore were used to evaluate the re-
lationships between physiologic and imaging measurements.
Results: Multivariate modeling for the 6MWD in 80 patients with GOLD 
grade U–II COPD showed that ADC (b = 0.34, P = .04), dif-
fusing capacity of the lung for carbon monoxide (b = 0.60, P = 
.0008), and residual volume/total lung capacity (b = 20.26, P = 
.02) were significant variables, while forced expiratory volume 
in 1 second (FEV1) and airway disease measurements were not. 
In 36 patients with GOLD grade III or IV disease, FEV1 (b = 
0.48, P = .01) was the only significant contributor in a multivar-
iate model for 6MWD. MR imaging emphysema measurements 
also made the greatest relative contribution to symptoms in pa-
tients with milder (GOLD grade U–II) COPD (ADC: b = 0.60, P 
= .005; RA950: b = 20.52, P = .02; FEV1: b = 20.45, P = .0002) 
and in grade III or IV disease (ADC: b = 0.95, P = .01; RA950: b 
= 20.62, P = .07; airway count: b = 20.49, P = .01).
Conclusion: In patients with mild-to-moderate COPD, MR imaging em-
physema measurements played a dominant role in the ex-
pression of exercise limitation, while both CT and MR imag-
ing measurements of emphysema explained symptoms.
q RSNA, 2015
Online supplemental material is available for this article.
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ex-smokers, and 3He ADC was related to 
both symptoms and exercise limitation. 
These data suggest that MR imaging mea-
surements of emphysema may uniquely 
explain clinically relevant symptoms and 
exercise limitation in otherwise healthy 
(on the basis of spirometric and CT 
findings) ex-smokers. All these previous 
reports suggested that imaging measure-
ments of emphysema and airway disease 
can be exploited to provide a better un-
derstanding of the phenotypes responsi-
ble for symptoms and exercise limitation 
in COPD. In many patients with COPD, 
it is difficult to understand variable exer-
cise abilities and symptoms on the basis 
of spirometric measurements of airflow 
limitation, which may only be modestly 
abnormal.
Therefore, in this study, we eval-
uated patients across Global Initiative 
for Chronic Obstructive Lung Disease 
(GOLD) COPD severity grades by us-
ing well-established clinical and physi-
ologic and emerging imaging measure-
ments. Given their high sensitivity, we 
measured by using thoracic computed 
tomography (CT) and hyperpolarized in-
haled gas magnetic resonance (MR) im-
aging (6,7). The large-scale COPDGene 
(8) and ECLIPSE (9) studies explored CT 
airway disease and emphysema measure-
ments of COPD and their progression. 
COPDGene provided evidence of the 
genetic determinants and heritability of 
emphysema (10,11), and its results dem-
onstrated that specific phenotypes may 
help predict COPD exacerbations (12). 
The ECLIPSE study showed the high 
variability of emphysema expression in 
COPD and that emphysema worsening 
is variable and related to smoking status 
and sex (13). Notwithstanding these 
findings, CT measurements of COPD 
have some fundamental limitations. For 
example, emphysema tends to be under-
estimated when lesions are smaller than 
0.5 cm (14), and this is relevant in pa-
tients with mild disease. Airway disease 
estimates are limited by the fundamen-
tal spatial resolution limits of CT (15), 
which result in an inherent bias because 
only survivor airways can be measured 
(16). Nevertheless, CT measurements of 
emphysema and airway disease are cor-
related with symptoms and exercise lim-
itation in COPD (17–20). Adding to this 
body of evidence was a recent study (21) 
in ex-smokers with normal FEV1 and CT 
findings but modestly abnormal diffusing 
capacity of the lung for carbon monox-
ide (Dlco) and abnormally elevated hy-
perpolarized helium 3 (3He) MR imaging 
apparent diffusion coefficients (ADCs). 
Importantly, abnormal Dlco and 3He 
ADCs reflected mild emphysema in these 
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Advances in Knowledge
 n Apparent diffusion coefficients 
(ADCs) derived by using hyper-
polarized helium 3 MR imaging 
(P = .04), diffusion capacity of 
the lung for carbon monoxide (P 
= .0008) and residual volume/
total lung capacity (P = .02) sig-
nificantly added to the multivar-
iate regression equation for 
6-minute walk distance (6MWD), 
but forced expiratory volume in 1 
second (FEV1), CT measure-
ments of emphysema and airway 
disease, and MR imaging ventila-
tion measurements did not.
 n A multivariate model for St 
George’s Respiratory Question-
naire symptom score showed that 
the ADC (P = .005) had the 
greatest relative contribution, fol-
lowed by the relative area of the 
CT attenuation histogram with 
attenuation of 2950 HU or less 
(P = .02) and FEV1 (P = .0002), 
but CT airway disease and MR 
imaging ventilation measurements 
were not significant contributors.
Implication for Patient Care
 n Imaging measurements of emphy-
sema help identify and determine 
disease phenotype in patients 
with mild chronic obstructive 
pulmonary disease (COPD) in 
whom FEV1 is modestly abnor-
mal and contribute to the under-
standing of the sources or trig-
gers for clinically important 
outcomes such as the 6MWD 
and COPD symptoms (eg, cough, 
sputum production, wheeze, and 
breathlessness).
Decades of research aimed at a better understanding of the path-ophysiology of chronic obstructive 
pulmonary disease (COPD) and toward 
new drug discovery have not resulted in 
therapies that alter disease progression 
(1). Improved outcomes and quality of 
life for patients with COPD have been 
elusive as well because treatments are 
currently developed on the basis of spi-
rometry measurements (2), which can-
not help distinguish between underlying 
COPD phenotypes and are relatively 
insensitive to mild or early disease 
(3–5). Moreover, symptoms and exer-
cise capacity are also heterogeneous 
in patients with mild or early COPD, 
in whom forced expiratory volume in 
1 second (FEV1) is only modestly ab-
normal. More sensitive and specific 
phenotype measurements may provide 
a better patient-oriented understanding 
of COPD outcomes, especially in mild 
or early disease.
COPD phenotypes of airway dis-
ease and emphysema can be directly 
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on the Health Protection Agency [UK] 
NRPB-SR250), the volumetric CT dose 
index was 4.4 mGy and the total effec-
tive dose was 1.8 mSv. On the basis of 
these values and the size-dependent 
conversion factors of 1.00–2.00, the 
size-specific dose estimates, which 
were calculated by using the approach 
described by Christner and colleagues 
(29), ranged from 9 to 5 mGy.
Image Analysis
All measurements were performed by 
an expert in quantitative MR imaging 
and CT image analysis (M.K). Hyperpo-
larized 3He MR imaging ventilation was 
measured by using a semiautomated ap-
proach (30) to generate ventilation de-
fect percentage (VDP)—the ventilation 
defect volume normalized to the tho-
racic cavity volume. Hyperpolarized 3He 
ADC measurements were generated as 
previously described (31). Thoracic CT 
images were evaluated by using Pulmo-
nary Workstation 2.0 (VIDA Diagnos-
tics, Coralville, Iowa). The relative area 
of the CT attenuation histogram with 
attenuation of 2950 HU or less (RA950), 
the 15th percentile of the CT attenua-
tion histogram (HU15) and the slope of 
the low-attenuation cluster frequency 
distribution were generated. CT airway 
count, lumen area, airway wall area per-
centage of the third- to fifth-generation 
airways, and airway wall thickness of 
airways with an internal perimeter of 10 
mm (Pi10) (15) were also generated.
Statistical Methods
Statistical analyses were performed by 
using SPSS Statistics V22 (IBM, Ar-
monk, NY). An unpaired two-tailed t 
test was used to compare the severe 
and mild-to-moderate COPD subgroups 
with respect to subject demographic 
and functional measurements. A Fisher 
exact test was used to compare the 
severe and mild-to-moderate COPD 
subgroups for sex. Multiple compari-
sons were adjusted by using the Holm-
Bonferroni correction (32); 15 P values 
were included in the multiple compar-
isons correction procedure for Table 1
, and 13 P values were included in the 
multiple comparisons correction proce-
dure for Table 2. Although the SGRQ 
GOLD-II, and n = 36 GOLD-III/IV); 
80 participants had mild-to-moderate 
COPD (all: age = 70 years 6 9, range: 
51–87 years; men: 72 years 6 9, range: 
51–87 years; women: 68 years 6 8, 
range: 52–80 years), and 36 patients 
had severe COPD (all: age = 70 years 
6 9, range: 48–86 years; men: 70 years 
6 10, range: 48–86 years; women: 69 
years 6 7, range: 61–82 years).
Pulmonary Function Testing, 6-Minute 
Walk Test, and St George’s Respiratory 
Questionnaire
All participants performed spirome-
try (MedGraphics, St Paul, Minn) ac-
cording to American Thoracic Society 
(ATS) guidelines (25). Whole-body 
plethysmography (MedGraphics) was 
used to measure lung volumes, and 
the attached gas analyzer was used to 
measure Dlco. The St George’s Respi-
ratory Questionnaire (SGRQ) was used 
with permission (26). The 6-minute 
walk test was also performed according 
to ATS guidelines (27) to measure the 
6-minute walk distance (6MWD).
Image Acquisition
MR imaging was performed by using 
a 3.0-T Discovery 750MR (GE Health-
care, Milwaukee, Wis) system. Con-
ventional hydrogen 1 MR imaging was 
performed as previously described (28) 
at an inspiratory breath hold after in-
halation of 1.0 L N2 from functional 
residual capacity (FRC) from a 1.0-
L Tedlar bag (Jensen Inert Products, 
Coral Springs, Fla). Hyperpolarized 3He 
static ventilation and diffusion-weighted 
imaging were also performed as previ-
ously described (28). CT volumes were 
acquired (at FRC plus 1 L N2 gas) by 
using a 64-section Lightspeed VCT 
system (GE Healthcare) within 10 mi-
nutes of MR imaging and approximately 
1 hour after salbutamol administration, 
as previously described (21). To reduce 
potential differences in lung volumes, 
subjects were transported in a wheel-
chair to CT, and images were acquired 
at inspiration breath-hold after inhala-
tion of 1 L N2 gas from FRC. No expi-
ration scans were acquired. Using our 
manufacturer settings and the ImPACT 
CT patient dosimetry calculator (based 
hypothesized that imaging measure-
ments of airway disease and emphy-
sema would help explain symptoms 
in all patients with COPD as well as 
in the subgroup of patients with mild-
to-moderate COPD. This is important 
because phenotypes that are related to 
patient-oriented outcomes can be used 
to characterize patients and perhaps 
guide treatment. Therefore, in patients 
with COPD, and particularly in patients 
with mild-to-moderate disease, we 
aimed to determine the role of imag-
ing measurements of emphysema and 
airway disease in determining COPD 
symptoms and exercise limitation.
Materials and Methods
Study Participants
Volunteers provided written informed 
consent to a protocol approved by a 
local research ethics board and Health 
Canada that was compliant with the Per-
sonal Information Protection and Elec-
tronic Documents Act and the Health 
Insurance Portability and Accountability 
Act. Participants were recruited from a 
local tertiary care center and by adver-
tisement and were between 50 and 85 
years of age, with a previous diagnosis 
of COPD and a smoking history of 10 or 
more pack-years. Details regarding sub-
ject recruitment for the study are pro-
vided elsewhere (22). Briefly, a total of 
231 subjects were enrolled in the study; 
16 were excluded owing to MR imaging 
incompatibilities, six refused patient 
consent, and four were unable to per-
form the 3He gas inhalation and breath 
hold. COPD severity was defined by us-
ing GOLD criteria (23). Volunteers with 
GOLD-Unclassified (GOLD-U) disease 
were identified on the basis of FEV1/
forced vital capacity  70% and FEV1 , 
80% predicted, as previously described 
(24). Fifteen patients with GOLD I 
disease have been described elsewhere 
(21); that previous study focused on 
ex-smokers without airflow limitation 
and motivated the current evaluation, 
the aim of which was to evaluate pa-
tients with GOLD I–IV COPD. In total, 
116 participants were evaluated (n = 
10 GOLD-U, n = 22 GOLD-I, n = 48 
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symptom subscore were generated by 
using the stepwise method and SAS 
9.2 software (SAS Institute, Cary, NC). 
Age, sex, body mass index, and smoking 
status were included in the models be-
cause they were previously shown to be 
significantly associated with SGRQ and 
6MWD (17–20). The stepwise selection 
physiologic and imaging measurements; 
results are provided Table E2 (online). 
To provide a better understanding of the 
underlying imaging phenotype measure-
ments that have the greatest relative 
contribution to COPD symptoms and 
exercise capacity, multivariable regres-
sion models for the 6MWD and SGRQ 
reports a total score as well as three 
subscores, we evaluated multivariable 
models for the SGRQ symptom sub-
score to focus on COPD symptoms. 
Importantly, SGRQ component scores 
have been validated in COPD (26). Uni-
variate Pearson correlations were per-
formed for the 6MWD and SGRQ with 
Table 2
Imaging Measurements
Parameter Patients with Mild-to-Moderate COPD (n = 80) Patients with Severe COPD (n = 36) All Patients (n = 116) P Value*
CT measurements
 RA950 (%) 7 6 8 17 6 12 11 6 10 ,.0001
 HU15 (HU) 2920 6 30 2948 6 21 2934 6 24 ,.0001
 LAC (D) 21.8 6 0.3 22 6 0 21.8 6 0.2 .48
 Pi10 (mm) 4.3 6 0.2 4.3 6 0.2 4.3 6 0.2 .99
 Third-generation WA (%) 57 6 6 55 6 12 56 6 6 .99
 Fourth-generation WA (%) 63 6 3 61 6 11 63 6 3 .84
 Fifth-generation WA (%) 65 6 2 63 6 12 65 6 2 .99
 Third-generation LA (mm2) 39 6 13 36 6 11 40 6 14 .99
 Fourth-generation LA (mm2) 18 6 5 17 6 5 18 6 5 .82
 Fifth-generation LA (mm2) 13 6 5 14 6 3 14 6 5 .84
 Airway count (n) 78 6 27 58 6 21 72 6 28 .0004
MR imaging measurements
 VDP (%) 13 6 8 26 6 8 18 6 10 ,.0001
 ADC (cm2/sec) 0.37 6 0.10 0.48 6 0.09 0.42 6 0.1 ,.0001
Note.—Data are means 6 standard deviations. LA = lumen area, LAC = low-attenuation cluster analysis power law exponent, WA = airway wall area.
* Significant differences (P , .05) were determined by using t tests for continuous variables and Fisher exact test for categoric variables. P values are Holm-Bonferroni adjusted for the comparison of 
mild-to-moderate and severe COPD subgroups.
Table 1
Study Participant Characteristics
Parameter Patients with Mild-to-Moderate COPD (n = 80) Patients with Severe COPD (n = 36) All Patients (n = 116) P Value*
Age (y)
 All patients 70 6 9 (51–87) 70 6 9 (48–86) 70 6 9 (48–87) .99
 Male patients 72 6 9 (51–87) 70 6 10 (48–86) 71 6 9 (48–97) .99
 Female patients 68 6 8 (52–80) 69 6 7 (61–82) 68 6 8 (52–82) .99
No. of male patients 49 23 72 .99
No. of pack-years 48 6 28 57 6 33 52 6 30 .99
Body mass index (kg/m2) 27 6 4 27 6 26 27 6 5 .99
FEV1 73 6 17 36 6 7 61 6 2 ,.0001
FEV1/FVC 59 6 12 38 6 8 52 6 15 ,.0001
TLC 112 6 17 125 6 17 116 6 18 .001
RV/TLC (%) 47 6 10 61 6 9 51 6 12 ,.0001
Dlco 61 6 19 43 6 18 56 6 21 ,.0001
SGRQ symptom subscore 44 6 22 64 6 19 51 6 22 .0001
6MWD (m) 400 6 77 320 6 32 378 6 89 .0003
Note.—Unless otherwise noted, data are means 6 standard deviations, with ranges in parentheses. Pulmonary function values are expressed as percentage predicted values. FVC = forced vital 
capacity, RV = residual volume, TLC = total lung capacity.
* Significant differences (P , .05) were determined by using t tests for continuous variables and the Fisher exact test for categoric variables. P values are Holm-Bonferroni adjusted for the comparison 
of mild-to-moderate and severe COPD subgroups.
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basis of the unstandardized b coeffi-
cients, to change the 6MWD more than 
the minimal clinically important differ-
ence (25 m), a relatively large change 
of approximately 0.10 cm2/sec for ADC 
was required for patients with mild-to-
moderate COPD.
For the model that explained the 
SGRQ symptom score in the mild-to-
moderate COPD subgroup, hyperpo-
larized 3He ADC significantly added to 
the regression equation (b = 0.60, P = 
.005), as did RA950 (b = 20.52, P = .02) 
and FEV1 (b = 20.45, P = .0002), with 
the greatest relative contribution stem-
ming from hyperpolarized 3He ADC. 
On the basis of the unstandardized b 
coefficient, to obtain a four-unit (the 
minimal clinically important difference) 
change in SGRQ, a relatively small 
change in ADC of approximately 0.03 
cm2/sec was required in the GOLD U–
II subgroup. For the GOLD III-IV sub-
group, ADC also provided the greatest 
relative contribution (b = 0.95, P = .01) 
to the regression equation for SGRQ 
symptoms, followed by CT RA950 (b = 
20.62, P = .07) and CT airway count 
(b = 20.49, P = .01). Finally, ADC also 
provided the greatest contribution to 
the regression equation for the SGRQ 
symptom score in all patients with 
COPD (b = 0.52, P = .003), and this 
was also reported to a lesser extent for 
FEV1 (b = 20.46, P , .0001), RA950 (b 
= 20.41, P = .03), and Pi10 (b = 0.15, 
P = .09).
Discussion
We evaluated emerging imaging and 
well-established physiologic measure-
ments in patients with COPD across a 
wide spectrum of severity and observed 
that (a) MR imaging emphysema mea-
surements contributed significantly in a 
multivariable model of the 6MWD for 
patients with mild-to-moderate COPD, 
while FEV1 and CT emphysema measure-
ments did not; and (b) in patients with 
mild-to-moderate or severe COPD, MR 
imaging emphysema measurements also 
provided a greater relative contribution 
than FEV1, CT emphysema, and other 
physiologic measurements in a multivar-
iable model for SGRQ symptoms.
for emphysema measurements (RA950: 
P , .0001; HU15: P , .0001; ADC: P , 
.0001), as well as for hyperpolarized 3He 
MR imaging VDP (P , .0001), but not 
CT airway measurements. The Figure 
shows center-section coronal hyper-
polarized 3He static ventilation images 
with corresponding hyperpolarized 3He 
ADC maps and CT low-attenuation 
cluster images for four representative 
GOLD I and GOLD II participants and 
a single GOLD III ex-smoker. As shown 
in the Figure, although the representa-
tive GOLD I-II subjects reported similar 
FEV1, a patient with COPD with more 
severe symptoms and greater activity 
limitation had brighter hyperpolarized 
3He ADC maps indicative of more se-
vere emphysematous destruction and 
larger/more numerous clusters of CT 
low-attenuation regions also reflective 
of more advanced bullous emphysema. 
These findings are similar to the more 
advanced COPD in the images in the 
patient with GOLD III disease also 
shown in the Figure.
Relationships for Imaging Phenotypes 
with Symptoms and Exercise
The univariate Pearson correlations for 
the 6MWD and SGRQ symptom sub-
score with physiologic and imaging mea-
surements in all patients with COPD 
are provided in Table E2 and Figure 
E1 (online); however, multivariate tests 
that take into account the complex in-
terrelationships among variables were 
also investigated. Table 3 shows mul-
tivariate regression models for 6MWD 
and SGRQ symptom score; variance 
inflation factors were acceptable for all 
variables. For the model that explained 
the 6MWD in the GOLD U–II subgroup, 
hyperpolarized 3He ADC significantly 
added to the regression equation (b = 
0.34, P = .04), as did Dlco (b = 0.60, P 
= .0008) and RV/TLC (b = 20.26, P = 
.02), but not FEV1. For the GOLD III-IV 
subgroup, only FEV1 added significantly 
to the regression equation (b = 0.48, 
P = .01). For all patients with COPD, 
hyperpolarized 3He ADC (b = 0.22, P = 
.09) and FEV1 (b = 0.26, P = .07) added 
to the regression equation for 6MWD, 
although Dlco (b = 0.40, P = .006) was 
the only significant contributor. On the 
method used a combination of forward 
and backward selection. At each step, 
variables were added to the model if the 
F statistic P  , .15 or were removed 
from the model if the F statistic P . .15. 
These steps continued until the addition 
of another variable to the model did not 
yield P , .15. For each independent 
variable included in the final multivar-
iable models, the unstandardized and 
standardized regression coefficients (b 
values) were reported. The unstandard-
ized b coefficients show how a single-
unit change in the independent variable 
influences a change in the dependent 
variable. We calculated the unit change 
that was required for a four-unit change 
in the SGRQ (33) and a 25-m change 
in the 6MWD (34), the previously 
published minimal clinically important 
difference values. The standardized b 
coefficients are estimates expressed in 
units of standard deviation, whereby 
the independent variable with the great-
est b coefficient had the greatest rela-
tive effect on the dependent variable 
in terms of standard deviation change. 
Multicollinearity among variables in the 
multivariable regression models was 
evaluated by using the variance infla-
tion factor and was deemed acceptable 
when less than 10 (35).
Results
Demographics and Pulmonary Function 
Measurements
Demographic, pulmonary function, 
SGRQ, and 6MWD measurements are 
shown in Table 1; a per-subject listing 
is provided in Table E1 (online). The 
mild-to-moderate (n = 80) and severe 
COPD (n = 36) subgroups were differ-
ent with respect to FEV1 (P , .0001), 
RV/TLC (P , .0001), Dlco (P , .0001), 
SGRQ symptom score (P , .0001), and 
6MWD (P = .0002), but there were 
no significant differences for age, sex, 
pack-years, or body mass index.
Imaging Measurements
Imaging measurements for the mild-to-
moderate and severe COPD subgroups 
are provided in Table 2. The COPD 
subgroups were significantly different 
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In patients with mild-to-moderate 
COPD and in whom FEV1 and airway 
disease measurements were not sig-
nificant contributors, the MR imaging 
measurement of emphysema, RV/TLC 
and Dlco had the greatest relative im-
pact on 6MWD; this is a novel finding. 
Although previous investigations in pa-
tients with moderate-to-severe COPD 
have revealed a strong relationship be-
tween CT emphysema measurements 
and exercise capacity (17–20), in the 
patients with COPD examined here, 
CT emphysema measurements did not 
significantly contribute to the model for 
exercise limitation. There is evidence 
that hyperpolarized 3He MR imaging 
ADC and Dlco may be more sensitive 
to early or mild emphysema (21), and 
this may explain why emphysema mea-
surements made by using MR imaging 
but not CT played a dominant role in 
explaining exercise limitation in mild-
to-moderate COPD. To provide con-
text, we recognize the important role 
that dyspnea and exercise intolerance 
play in milder COPD, as perviously 
described (3–5,36). Therefore, in this 
relatively small group of participants, 
exercise limitation in the patients with 
mild COPD may be related to relatively 
modest parenchymal abnormalities 
that can be sensitively detected by us-
ing inhaled gas MR imaging. Certainly, 
routine clinical assessment using Dlco 
is also helpful, but the finding of mod-
estly abnormal Dlco itself is not diag-
nostic for emphysema in patients with 
COPD, in whom a wide variety of other 
cardiopulmonary diseases is possible.
We also found, somewhat surpris-
ingly, that emphysema measurements 
had a greater influence on symptoms 
than airway disease measurements in 
severe COPD and in the subgroup of 
patients with mild-to-moderate COPD. 
In this regard, it is somewhat intuitive 
to relate specific COPD symptoms like 
cough and breathlessness to airway ab-
normalities, especially because previous 
work showed that in moderate-to-severe 
COPD, airway disease measurements 
provide the greatest contribution to 
symptoms (18,20). However, patients 
with COPD with mainly emphysema 
also report greater rates of dynamic 
Images in representative patients with mild-to-moderate or severe COPD. Left-to-right: hy-
perpolarized 3He MR imaging ventilation images, 3He MR imaging ADC maps, and CT images 
showing low-attenuating clusters (LAC) for subject 27 (S27), a 74-year-old man (FEV
1
 = 86% 
predicted value, 6MWD = 486 m, SGRQ symptom subscore = 6, VDP = 6%, ADC = 0.37 
cm2/sec, Pi10 = 4.1 mm, RA
950
 = 6%); subject 28 (S28), a 73-year-old man (FEV
1
 = 85% 
predicted value, 6MWD = 360 m, SGRQ symptom subscore = 43, VDP = 9%, ADC = 0.45 
cm2/sec , Pi10 = 4.1 mm, RA
950
 = 4%); subject 35 (S35), a 76-year-old man (FEV
1
 = 77% 
predicted value, 6MWD = 357 m, SGRQ symptom subscore = 37, VDP = 7%, ADC = 0.30 
cm2/sec, Pi10 = 4.4 mm, RA
950
 = 2%); subject 36 (S36), a 77-year-old woman (FEV
1
 = 77% 
predicted value, 6MWD = 240 m, SGRQ symptom subscore = 69, VDP = 13%, ADC = 0.56 
cm2/sec, Pi10 = 4.2 mm, RA
950
 = 13%); and subject 102 (S102), a 74-year-old man (FEV
1
 = 
34% predicted value, 6MWD = 282 m, SGRQ symptom subscore = 55, VDP = 34%, ADC = 
0.50 cm2/sec, Pi10 = 4.2 mm, RA
950
 = 18%).
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hyperinflation during exercise, leading 
to lower peak oxygen consumption and 
greater dyspnea (37). Therefore, it is 
also possible that the presence and ex-
tent or severity of emphysema may be 
directly related to “shortness of breath” 
and “wheezing”—two domains included 
in the symptom component of the 
SGRQ questionnaire. Another possible 
explanation for why CT and MR imag-
ing airway disease measures were not 
significant contributors in the multivari-
ate models may be related to the inher-
ent limitations of these measurements. 
CT airway disease measurements based 
on airway morphometry are limited 
by the spatial resolution of CT to the 
larger, more central airways greater 
than 2 mm in diameter. Moreover, MR 
imaging ventilation measurements may 
represent the contributions of both em-
physema and airway disease, as previ-
ously described in moderate-to-severe 
COPD (38). Nevertheless, here we 
demonstrated that CT- and MR imag-
ing–derived emphysema measurements 
were related to COPD symptoms and 
may better explain how patients with 
COPD feel at rest and when walking.
A limitation of our study was that 
the sample size of 116 patients, which 
was much smaller than in the COPD-
Gene (18), ECLIPSE (20), and Genetic 
COPD Study (GenKOLS) (17) studies. 
Importantly, another limitation was 
that this study was performed at a sin-
gle center. Multicenter studies like the 
PHIL trial, which is the only multicenter 
study incorporating both CT and hyper-
polarized 3He MR imaging in patients 
with COPD to date (39), are required 
for external validity of the findings. 
In addition, a control group of older 
never-smokers was not included in the 
main study, and so comparisons with 
healthy volunteers could not be made. 
We were also limited by not acquiring 
CT images at end-expiration in addition 
to end-inspiration. CT relative area  of 
2856 HU or less is well known to be as-
sociated with air trapping and therefore 
would have been an important measure 
to include in our analysis. Furthermore, 
the evaluation of exercise limitation and 
symptoms in this study was limited be-
cause symptoms were not evaluated by 
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